Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Wants More Examples Of Real-World Data Use

Executive Summary

CDER Director Woodcock says for regulatory purposes, using real-world data likely will remain a case-by-case decision.

Advertisement

Related Content

Real-World Data: Precertification Could Aid Use For Regulatory Decisions
How A Rapid, Well-Messaged US FDA Offense Is Driving Spectators To Their Feet And Twitter Accounts
How a Rapid and Well-Messaged US FDA Offense Is Driving Spectators to Their Feet and Twitter Accounts
Real-World Evidence Challenges: Death Among Toughest Data Points To Measure
Real-World Evidence Could Help Relax Clinical Trial Enrollment Criteria
Real-World Data Could Get Boost From Trial Replication Project
Real World Evidence Benefits, Limits Explored In US FDA Demonstrations
Real-World Evidence: Advice, Principles And Examples Emerge From FDA

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123625

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel